A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

Clinical trial NCT05212532 · UNKNOWN

Trial details

NCT number: NCT05212532
Sponsor: EOM Pharmaceuticals
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

COVID-19 Pneumonia COVID-19 Respiratory Infection COVID-19 Acute Respiratory Distress Syndrome

Start date: 2021-08-09
Primary completion: 2022-02-28
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.